Atheroma; Carotid ArteryCAPGADNCT07364058
Assessment of Platelet-derived GARP in Atherosclerotic Disease
An observational study of Atheroma; Carotid Artery and Atheromatosis, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atheroma; Carotid Artery, Atheromatosis
- What is being tested?
- Tissue sample and data collection
- How many people
- 200 participants
- Where
- 1 siteBelgium
- Study dates
- Feb 2026to Jan 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.
Who may be able to join
- Older than 18 years
- Able to give informed consent
- Undergoing carotid or femoral endarterectomy
Who cannot join
- Younger than 18 years
- Pregnant
- Dialysis
- Unable to give informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site
Cliniques Universitaires Saint-Luc
Brussels, 1200
Louis Charki, Medical Degree, +3224362014, louis.charki@uclouvain.be
Christophe Beauloye, Medical Degree
About this study
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
- Conditions
- Atheroma; Carotid Artery, Atheromatosis
- Being tested
- Tissue sample and data collection
- Keywords
- Atheroma, Atherosclerosis, GARP, LRRC32
- Medical subject headings
- Carotid Artery Diseases, Atherosclerosis, Plaque, Atherosclerotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tissue sample and data collectionOther
Tissue sample and data collection
| Study group | Role | What they receive |
|---|---|---|
| Endarterectomy population | This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy. Receives: Other: Tissue sample and data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
GARP Expression in Platelets
The number of cells/area expressing the GARP protein will be assessed
Measured: Throughout the entire study, approximately during 3 years
Secondary outcomes (2)
GARP Expression T Regulating Cells
The number of cells expressing GARP will be assessed as a number of cells / area
Measured: Throughout the entire study, approximately during 3 years
GARP Expression General
The type of cells expressing GARP will be assessed as a number of cells / area
Measured: Throughout the entire study, approximately during 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study startFeb 2026 (estimated)
- Primary completionJan 2029 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atheroma; Carotid ArteryStudies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Responsible party
- Sponsor
- Investigators
- Christophe Beauloye, Medical Degree, Principal investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07364058
- Sponsor's protocol ID
- CAPGAD
- Acronym
- CAPGAD
- Status last verified
- Jan 2026
- First submitted
- 15 Jan 2026
- Last updated
- 27 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Platelet-derived GARP in Atherosclerotic Disease
- ClinicalTrials.gov ID
- NCT07364058
- Acronym / sponsor ID
- CAPGAD / CAPGAD
- Conditions
- Atheroma; Carotid Artery, Atheromatosis
- Keywords
- Atheroma, Atherosclerosis, GARP, LRRC32
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Study start
- Feb 2026 (estimated)
- Primary completion
- Jan 2029 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Endarterectomy population | – | Other: Tissue sample and data collectionThis group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.
Key inclusion criteria (3 listed)
- Older than 18 years
- Able to give informed consent
- Undergoing carotid or femoral endarterectomy
Key exclusion criteria (4 listed)
- Younger than 18 years
- Pregnant
- Dialysis
- Unable to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tissue sample and data collectionTissue sample and data collection | Other | Endarterectomy population |
Primary outcome
GARP Expression in Platelets
Time frame: Throughout the entire study, approximately during 3 years
The number of cells/area expressing the GARP protein will be assessed
2 secondary outcomes
GARP Expression T Regulating Cells
Time frame: Throughout the entire study, approximately during 3 years
GARP Expression General
Time frame: Throughout the entire study, approximately during 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Atheroma; Carotid Artery
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Recruiting
Carotid Plaque Characterization Using Innovative Ultrasound Techniques
Carotid Atheroma
Recruiting
Predicting High-Risk Carotid Plaque: Integrating radioMics and biomEchanics
Carotid Artery, Carotid Arteriosclerosis
Not yet recruiting
Effects of Rosa Roxburghii Tratt Freeze-Dried Powder on Carotid Atherosclerotic Plaques: A Real-World Study
Carotid Artery Plaques, Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Christophe Beauloye, Medical Degree principal investigator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atheroma; Carotid Artery and Atheromatosis, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Louis Charki, Medical Degree (+3224362014, louis.charki@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
GARP Expression in Platelets (time frame: Throughout the entire study, approximately during 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2026.